Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis

Autor: Lisa Baumgartner, Gianluca Galeno, Florian A. F. Schuler, Andrin Good, Carlijn R. Hooijmans, Benjamin V. Ineichen, Tarzis Jung, Rob B. M. de Vries, Marc P. Schneider, Martin Hlavica, Nicolas Good
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
medicine.medical_specialty
Encephalomyelitis
Autoimmune
Experimental
Multiple Sclerosis
MEDLINE
Tocopherols
lcsh:Medicine
610 Medicine & health
Article
Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2]
03 medical and health sciences
Cuprizone
Mice
0302 clinical medicine
Ethidium
medicine
Animals
Nerve Growth Factors
Remyelination
Intensive care medicine
Eye Proteins
lcsh:Science
Myelin Sheath
Serpins
Oligodendrocyte Precursor Cells
Platelet-Derived Growth Factor
Multidisciplinary
Study quality
business.industry
Multiple sclerosis
lcsh:R
Lysophosphatidylcholines
medicine.disease
Bench to bedside
Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]
Clinical trial
Disease Models
Animal
Oligodendroglia
030104 developmental biology
medicine.anatomical_structure
Meta-analysis
Experimental pathology
lcsh:Q
business
030217 neurology & neurosurgery
Demyelinating Diseases
Zdroj: Scientific Reports, Vol 9, Iss 1, Pp 1-17 (2019)
Hooijmans, Carlijn R; Hlavica, Martin; Schuler, Florian; Good, Nicolas; Good, Andrin; Baumgartner, Lisa; Galeno, Gianluca; Schneider, Marc P; Jung, Tarzis; de Vries, Rob; Ineichen, Benjamin V (2019). Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis. Scientific reports, 9(1), p. 822. Springer Nature 10.1038/s41598-018-35734-4
Scientific Reports
Scientific Reports, 9
Scientific Reports, 9 (1)
ISSN: 2045-2322
DOI: 10.1038/s41598-018-35734-4
Popis: An unmet but urgent medical need is the development of myelin repair promoting therapies for Multiple Sclerosis (MS). Many such therapies have been pre-clinically tested using different models of toxic demyelination such as cuprizone, ethidium bromide, or lysolecithin and some of the therapies already entered clinical trials. However, keeping track on all these possible new therapies and their efficacy has become difficult with the increasing number of studies. In this study, we aimed at summarizing the current evidence on such therapies through a systematic review and at providing an estimate of the effects of tested interventions by a meta-analysis. We show that 88 different therapies have been pre-clinically tested for remyelination. 25 of them (28%) entered clinical trials. Our meta-analysis also identifies 16 promising therapies which did not enter a clinical trial for MS so far, among them Pigment epithelium-derived factor, Plateled derived growth factor, and Tocopherol derivate TFA-12.We also show that failure in bench to bedside translation from certain therapies may in part be attributable to poor study quality. By addressing these problems, clinical translation might be smoother and possibly animal numbers could be reduced.
Scientific Reports, 9 (1)
ISSN:2045-2322
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje